Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 67

Results For "AIM"

2350 News Found

Lupin receives highest ESG rating from CDP for climate change and water security
Sustainability | January 24, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability


Telangana unveils ambitious next-gen Life Sciences Policy at Davos
News | January 24, 2026

Telangana unveils ambitious next-gen Life Sciences Policy at Davos

A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics


Functional Gut Clinic launches UK’s first boutique GI clinical trials division
Clinical Trials | January 23, 2026

Functional Gut Clinic launches UK’s first boutique GI clinical trials division

Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced


Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies
R&D | January 23, 2026

Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies

The partnership initially will focus on cardiovascular and kidney diseases


iRegene’s Parkinson’s therapy gains FDA designation
News | January 21, 2026

iRegene’s Parkinson’s therapy gains FDA designation

The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases


Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing
News | January 21, 2026

Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing

The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing


Novo Nordisk deepens Aspect Biosystems alliance in push for curative diabetes cell therapies
News | January 21, 2026

Novo Nordisk deepens Aspect Biosystems alliance in push for curative diabetes cell therapies

Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies


Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
R&D | January 21, 2026

Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half

The study evaluated patients with stage III/IV melanoma after complete tumor resection